Table 2.
Characteristics of FH patients on LLT classified according to attainment of LDL-c goal
| LDL-Ch < 100 mg/dL (N = 33) | LDL-Ch ≥ 100 mg/dL (N = 932)A | P-value | |
|---|---|---|---|
| Male gender, N(%) | 18 (54.5) | 454 (48.7) | 0.510 |
| Cases ≥ 45 years, N (%) | 24 (72.7) | 492 (52.8) | 0.024 |
| Age (y)* | 54.7 (SD:14.5) | 47.4 (SD:14.2) | 0.004 |
| History of CVD, N (%) | 10 (30.3) | 153 (16.4) | 0.036 |
| Type 2 Diabetes, N (%) | 4 (12.1) | 33 (3.5) | 0.012 |
| High Blood Pressure, N (%) | 10 (30.3) | 157 (16.8) | 0.045 |
| Current smokers, N (%) | 5 (15.2) | 239 (25.6) | 0.173 |
| BMI (Kg/m2)* | 26.6 (SD:4.0) | 26.7 (SD:4.6) | 0.882 |
| Control by Specialist, N (%) | 16 (59.3) | 293 (53.2) | 0.677 |
| Null/Defective mutations, N (%) | 16/14(48.5/42.4) | 541/311(58.0/33.4) | 0.525 |
| Years on statin treatment* | 7.9 (SD:8.1) | 6.8 (SD:6.3) | 0.334 |
| ≥ 50% LDL-c reduction, N (%) | 21 (63.6) | 471 (49.9) | 0.254 |
| Monotherapy with Statins, N (%) | 11 (33.0) | 565 (60.6) | 0.002 |
| Maximum Statin dose, N (%) | 1(3.0)B | 134 (14.4) B | 0.229 |
| Combined Therapy, N (%)C | 18 (54.5) | 270 (29.0) | 0.002 |
| Maximum Therapy, N (%)D | 6 (18) B | 124 (13.3) B | 0.238 |
FH, Familial hypercholesterolemia; LLT, Lipid-lowering therapy; CVD, Cardiovascular disease; BMI (Body mass index) (A) LDL-ch levels were uknown in 91 cases; (B) percentage calculated with total cases in each group. (C) Combined therapy includes only any statin + ezetimibe 10 mg; (D), Maximum therapy includes any statin at maximum dose + ezetimibe 10 mg; *Mean and Standard Deviation (SD).